Zafgen's second try at Prader-Willi syndrome triggers another safety alarm in preclinical tox study
Zafgen’s $ZFGN latest shot at creating the first therapy to treat patients with rare cases of obesity brought on by Prader-Willi syndrome has hit a safety alarm before the drug even managed to make it into the clinic.
The successor to beloranib — which blew up with spectacular effect several years ago following a clinical hold by the FDA — ZGN-1258 was supposed to be the biotech’s comeback drug in the field. Instead, the biotech reported after the market closed on Monday that it is suspending plans for an IND after researchers tracked muscle deterioration in a rodent model of the disease.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.